Zacks Investment Research cut shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) from a hold rating to a sell rating in a report issued on Tuesday, October 17th.
According to Zacks, “Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson’s disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington’s disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
VYGR has been the topic of a number of other research reports. ValuEngine upgraded shares of Voyager Therapeutics from a strong sell rating to a sell rating in a report on Friday, September 1st. Raymond James Financial, Inc. started coverage on shares of Voyager Therapeutics in a report on Thursday, October 12th. They set an outperform rating and a $35.00 price target on the stock. Chardan Capital reiterated a hold rating on shares of Voyager Therapeutics in a report on Sunday, September 10th. BidaskClub upgraded shares of Voyager Therapeutics from a strong sell rating to a sell rating in a report on Thursday, July 13th. Finally, Stifel Nicolaus restated a buy rating and set a $33.00 price objective on shares of Voyager Therapeutics in a research report on Tuesday, June 27th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company. The company currently has an average rating of Buy and an average target price of $28.75.
Voyager Therapeutics (VYGR) traded up 4.78% during trading on Tuesday, reaching $22.57. The company’s stock had a trading volume of 262,602 shares. The company has a 50-day moving average of $19.30 and a 200 day moving average of $12.04. Voyager Therapeutics has a one year low of $8.10 and a one year high of $25.99. The firm’s market cap is $607.20 million.
Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Tuesday, August 8th. The company reported ($0.73) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.11). The business had revenue of $1.18 million during the quarter, compared to analysts’ expectations of $3.27 million. Voyager Therapeutics had a negative return on equity of 46.15% and a negative net margin of 712.22%. Analysts expect that Voyager Therapeutics will post ($2.87) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This story was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.dispatchtribunal.com/2017/10/28/voyager-therapeutics-inc-vygr-rating-lowered-to-sell-at-zacks-investment-research.html.
In other news, insider Bernard Ravina sold 5,490 shares of the firm’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $10.00, for a total transaction of $54,900.00. Following the sale, the insider now directly owns 17,157 shares in the company, valued at approximately $171,570. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 32,940 shares of company stock worth $490,092 over the last 90 days. Insiders own 8.00% of the company’s stock.
Several hedge funds have recently made changes to their positions in the company. Raymond James Financial Services Advisors Inc. bought a new stake in shares of Voyager Therapeutics during the 3rd quarter valued at $1,122,000. Nationwide Fund Advisors raised its position in shares of Voyager Therapeutics by 81.5% during the 3rd quarter. Nationwide Fund Advisors now owns 19,779 shares of the company’s stock valued at $407,000 after purchasing an additional 8,884 shares during the period. California State Teachers Retirement System raised its position in shares of Voyager Therapeutics by 8.4% during the 2nd quarter. California State Teachers Retirement System now owns 25,811 shares of the company’s stock valued at $231,000 after purchasing an additional 2,000 shares during the period. State Street Corp grew its stake in Voyager Therapeutics by 11.8% during the second quarter. State Street Corp now owns 184,526 shares of the company’s stock valued at $1,653,000 after acquiring an additional 19,471 shares in the last quarter. Finally, DAFNA Capital Management LLC grew its stake in Voyager Therapeutics by 187.2% during the second quarter. DAFNA Capital Management LLC now owns 204,808 shares of the company’s stock valued at $1,835,000 after acquiring an additional 133,488 shares in the last quarter. Hedge funds and other institutional investors own 40.74% of the company’s stock.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
Get a free copy of the Zacks research report on Voyager Therapeutics (VYGR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.